Estimating the cost-effectiveness of Vortioxetine versus Desvenlafaxine as first line Therapy for mild to moderate Major depressive Disorder in remitted patients
May 1, 2015, 00:00
10.1016/j.jval.2015.03.711
https://www.valueinhealthjournal.com/article/S1098-3015(15)00768-8/fulltext
Title :
Estimating the cost-effectiveness of Vortioxetine versus Desvenlafaxine as first line Therapy for mild to moderate Major depressive Disorder in remitted patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00768-8&doi=10.1016/j.jval.2015.03.711
First page :
A121
Section Title :
Individual's Health
Open access? :
No
Section Order :
143